HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients

Journal of the National Cancer Institute

Volumn 108, Issue 6, 2016, Pages

  Castellsagué, Xavier ^a,c   Alemany, Laia ^b,c   Quer, Miquel ^d   Halec, Gordana ^e   Quirós, Beatriz ^b   Tous, Sara ^b   Clavero, Omar ^b   Alòs, Llúcia ^f   Biegner, Thorsten ^g   Szafarowski, Tomasz ^h   Alejo, Maria ⁱ   Holzinger, Dana ^e   Cadena, Enrique ^j,k   Claros, Edith ^l   Hall, Gillian ^m   Laco, Jan ⁿ   Poljak, Mario ^o   Benevolo, Maria ^p   Kasamatsu, Elena ^q   Mehanna, Hisham ^r   Ndiaye, Cathy ^s   Guimerà, Núria ^t   Lloveras, Belen ^u   León, Xavier ^d   Ruiz Cabezas, Juan C ^v   Alvarado Cabrero, Isabel ^w   Kang, Chang Suk ^x   Oh, Jin Kyoung ^y   Garcia Rojo, Marcial ^z   Iljazovic, Ermina ^aa   Ajayi, Oluseyi F ^ab   Duarte, Flora ^ac   Nessa, Ashrafun ^ad   Tinoco, Leopoldo ^ae   Duran Padilla, Marco A ^af   Pirog, Edyta C ^ag   Viarheichyk, Halina ^ah   Morales, Hesler ^ai   Costes, Valérie ^aj   Félix, Ana ^ak   Germar, Maria Julieta V ^al   Mena, Marisa ^b   Ruacan, Arzu ^am,an   Jain, Asha ^ao   Mehrotra, Ravi ^ap   Goodman, Marc T ^aq,ar   Lombardi, Luis Estuardo ^as   Ferrera, Annabelle ^at   Malami, Sani ^au,av   Albanesi, Estela I ^aw   Dabed, Pablo ^ax   Molina, Carla ^ay   López Revilla, Rubén ^az   Mandys, Václav ⁿ   González, Manuel E ^ba   Velasco, Julio ^bb   Bravo, Ignacio G ^b   Quint, Wim ^t   Pawlita, Michael ^e   Muñoz, Nubia ^j   Sanjosé, Silvia De ^b,c   Xavier Bosch, F ^b   more..

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d Hospital Sant Pau   (Spain)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f UNIVERSITY OF BARCELONA   (Spain)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h MEDICAL UNIVERSITY OF WARSAW   (Poland)

ⁱ HOSPITAL GENERAL DE CATALUNYA   (Spain)

^j Instituto Nacional de Cancerología   (Colombia)

^k UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^l Laboratorio Privado de Patología Oncos   (United States)

^m MANCHESTER ROYAL INFIRMARY   (United Kingdom)

ⁿ CHARLES UNIVERSITY   (Czech Republic)

^o UNIVERSITY OF LJUBLJANA   (Slovenia)

^p REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^q Instituto de Investigaciones en Ciencias de la Salud Universidad Nacional de Asuncion   (Paraguay)

^r UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^s UNIVERSITÉ DE MONTRÉAL   (Canada)

^t DDL DIAGNOSTIC LABORATORY   (Netherlands)

^u UNIVERSITAT POMPEU FABRA   (Spain)

^v SOLCA   (Ecuador)

^w INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^x The Catholic University of Korea   (South Korea)

^y National Cancer Center   (South Korea)

^z HOSPITAL DE JEREZ   (Spain)

^aa University Clinical Center   (Bosnia and Herzegovina)

^ab UNIVERSITY OF LAGOS   (Nigeria)

^ac Emma Romero de Callejas Centro de Cancer   (Honduras)

^ad BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

^ae Hospital Oncológico SOLCA Núcleo de Quito   (Ecuador)

^af HOSPITAL GENERAL DE MÉXICO   (Mexico)

^ag WEILL CORNELL MEDICAL CENTER   (United States)

^ah GOMEL STATE MEDICAL UNIVERSITY   (Belarus)

^ai Instituto de Cancerología dr Bernardo Del Valle S Guatemala   (Guatemala)

^aj GUI DE CHAULIAC HOSPITAL   (France)

^ak INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^al UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^am KOÇ UNIVERSITY   (Turkey)

^an HACETTEPE UNIVERSITY   (Turkey)

^ao Cancer Prevention and Relief Society   (India)

^ap MLN MEDICAL COLLEGE   (India)

^aq INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

^ar UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^as CEDARS SINAI MEDICAL CENTER   (United States)

^at Hospital General San Juan de Dios Guatemala   (Guatemala)

^au NATIONAL AUTONOMOUS UNIVERSITY OF HONDURAS   (Honduras)

^av BAYERO UNIVERSITY   (Nigeria)

^aw Ministerio de Salud de la provincia de Buenos Aires   (Argentina)

^ax UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^ay UNIVERSITY OF CHILE   (Chile)

^az INSTITUTO POTOSINO DE INVESTIGACIÓN CIENTÍFICA Y TECNOLÓGICA   (Mexico)

^ba Infectology and Epidemiology Service   (Colombia)

^bb HOSPITAL SAN AGUSTÍN   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; PROTEIN P53; VIRUS DNA; CCND1 PROTEIN, HUMAN; PROLINE RICH PROTEIN; TUMOR MARKER;

ADENOSQUAMOUS CARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER TISSUE; CENTRAL EUROPEAN; DNA DETERMINATION; EASTERN EUROPE; FEMALE; GENDER; GEOGRAPHIC DISTRIBUTION; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; HYPOPHARYNX CANCER; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; NASOPHARYNX CANCER; NORTHERN EUROPEAN; OROPHARYNX CANCER; PHARYNX CANCER; PRIORITY JOURNAL; QUALITY CONTROL; SOUTH AMERICA; SOUTHERN EUROPE; SQUAMOUS CELL CARCINOMA; UNDIFFERENTIATED CARCINOMA; WART VIRUS; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; CROSS-SECTIONAL STUDY; GENETICS; GENOTYPE; HEAD AND NECK TUMOR; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; OROPHARYNX TUMOR; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; VIROLOGY;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CROSS-SECTIONAL STUDIES; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; SALIVARY PROLINE-RICH PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84977080592     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv403     Document Type: Article

References (27)

1. A review of human carcinogens. Part B: Biological agents/IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, France: International Agency for Research on Cancer Monographs; 2009.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
3. IARC Monographs on the evaluation of carcinogenic risks to humans, vol. 83. Tobacco Smoke and Involuntary Smoking. Lyon, France: International Agency for Research on Cancer Monographs; 2004.
4. IARC Monographs on the evaluation of carcinogenic risks to humans, vol. 44. Alcohol drinking. Lyon, France: International Agency for Research on Cancer Monographs; 1988.
5. Gillison ML, Alemany L, Snijders PJ, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine. 2012;30(Suppl 5):F34-F54.
6. Herrero R, Castellsague X, Pawlita M, et al; IARC Multicenter Oral Cancer Study Group. Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95(23):1772-1783.
7. Holzinger D, Schmitt M, Dyckhoff G, Benner A, Pawlita M, Bosch FX. Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res. 2012;72(19):4993-5003.
8. Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319-1331
9. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-475.
10. de Sanjose S, Quint WG, Alemany L, et al; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-1056.
11. BarnesL, EvesonJW, ReichartP, SidranskyD, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. International Agency of Research on Cancer. In press: Lyon 2005.
12. Geraets D, Alemany L, Guimera N, et al; RIS HPV TT study group. Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. J Pathol. 2012;228(4):534-543.
13. Alemany L, Saunier M, Alvarado-Cabrero I, et al; HPV VVAP Study Group. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136(1):98-107.
14. Halec G, Schmitt M, Dondog B, et al. Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int J Cancer. 2013;132(1):63-71.
15. Halec G, Holzinger D, Schmitt M, et al. Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma. Br J Cancer. 2013;109(1):172-183.
16. Holzinger D, Flechtenmacher C, Henfling N, et al. Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway. Int J Cancer. 2013;133(6):1389-1399.
17. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer. 2007;121(11):2465-2472.
18. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed February 17, 2015.
19. Robinson M, Schache A, Sloan P, Thavaraj S. HPV specific testing: A requirement for oropharyngeal squamous cell carcinoma patients. Head Neck Pathol. 2012;6(Suppl 1): S83-S90.
20. Halec G, Alemany L, Lloveras B, et al; Retrospective International Survey and HPV Time Trends Study Group. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol. 2014;234(4):441-451.
21. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol. 2012;13(6):607-615.
22. Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6);djv086 doi:10.1093/jnci/djv086.
23. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550-4559.
24. Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35(5):747-755.
25. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-4301.
26. Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009;125(2):362-366.
27. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009;10(4):321-322.